Fluidigm to Use $18M Financing to Support R&D, Marketing Efforts | GenomeWeb

By Justin Petrone

Fluidigm plans to invest $18.2 million in new financing on R&D for its gene-expression, genotyping, and sequence-capture applications, and to grow its global sales and marketing force, according to a company representative.

Spokesperson Howard High told BioArray News this week that the new funding, raised from a private placement of its stock, should also provide Fluidigm with "enough cushion to reach profitability."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.